Alnylam Pharmaceuticals, Inc.
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2016 | $342.6M | $1.26B | $193.6M |
| FY2017 | $228.3M | $1.99B | $645.4M |
| FY2018 | $272.8M | $1.57B | $420.1M |
| FY2019 | $956.4M | $2.40B | $547.2M |
| FY2020 | $2.39B | $3.41B | $496.6M |
| FY2021 | $3.06B | $3.64B | $820.0M |
| FY2022 | $3.70B | $3.55B | $866.4M |
| FY2023 | $4.05B | $3.83B | $812.7M |
| FY2024 | $4.17B | $4.24B | $966.4M |
| FY2025 | $4.18B | $4.97B | $1.66B |